{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:36:01Z","timestamp":1781325361420,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Global Services, LLC"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.08.010","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T23:44:54Z","timestamp":1536709494000},"page":"78-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis"],"prefix":"10.1016","volume":"103","author":[{"given":"Susan","family":"Feyerabend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Van Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Porre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Roiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seye","family":"Abogunrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koufopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2018.08.010_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/CCO.0000000000000172","article-title":"Understanding heterogeneity of treatment effect in prostate cancer","volume":"27","author":"Aly","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.010_bib2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.010_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.08.010_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.08.010_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2018.08.010_bib6","article-title":"Quality of life (QOL) analysis from CHAARTED: chemohormonal androgen ablation randomized trial in prostate cancer (E3805). ASCO GENITOURINARY conference 2016, San francisco","volume":"vol. 34","author":"Patrick-Miller","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.08.010_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.08.010_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.010_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"10024","key":"10.1016\/j.ejca.2018.08.010_bib10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2018.08.010_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157660","article-title":"Efficacy and safety of combined androgen deprivation therapy (ADT) and docetaxel compared with ADT alone for metastatic hormone-naive prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Botrel","year":"2016","journal-title":"PLoS One"},{"issue":"2_suppl","key":"10.1016\/j.ejca.2018.08.010_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2016.34.2_suppl.259","article-title":"Chemotherapy in metastatic hormone-na\u00efve\u00a0prostate cancer: pooled analysis of randomized clinical trials","volume":"34","author":"Fabbri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2_suppl","key":"10.1016\/j.ejca.2018.08.010_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/jco.2016.34.2_suppl.188","article-title":"Androgen-deprivation therapy plus docetaxel-based chemotherapy in metastatic hormone-sensitive prostate cancer. A meta-analysis of randomized clinical trials","volume":"34","author":"Ramos-Esquivel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.08.010_bib14","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.urolonc.2016.03.003","article-title":"Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Ramos-Esquivel","year":"2016","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.010_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2015.09.013","article-title":"Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis","volume":"69","author":"Tucci","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.010_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2018.08.010_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e16526","article-title":"Androgen deprivation therapy alone or with docetaxel in hormone naive metastatic prostate cancer: meta-analysis of randomized phase III trials","volume":"34","author":"Zekri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2018.08.010_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e16505","article-title":"Docetaxel in the treatment of metastatic hormone-sensitive and castration-resistant prostate cancer: a meta-analysis","volume":"34","author":"Zhang","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.08.010_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.eururo.2017.09.029","article-title":"Updated guidelines for metastatic hormone-sensitive prostate cancer: abiraterone acetate combined with castration is another standard","volume":"73","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2018.08.010_bib20","series-title":"Guidelines on prostate cancer","author":"European Association of Urology","year":"2017"},{"key":"10.1016\/j.ejca.2018.08.010_bib21","series-title":"NCCN clinical practice guidelines in oncology (NCCN Guideline\u00ae) prostate cancer. Version 2.2017","author":"National Comprehensive Cancer Network","year":"2017"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2018.08.010_bib22","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2018.08.010_bib23","article-title":"What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis","volume":"28","author":"Vale","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.08.010_bib24","article-title":"Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis","author":"Wallis","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ejca.2018.08.010_bib25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl_5","key":"10.1016\/j.ejca.2018.08.010_bib26","article-title":"Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476)","volume":"28","author":"Sydes","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.08.010_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2018.08.010_bib28","series-title":"Technology appraisal guidance","author":"National Institute for Health and Care Excellence (NICE)","year":"2017"},{"key":"10.1016\/j.ejca.2018.08.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.12.009","article-title":"Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial","author":"Buelens","year":"2018","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.010_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ejca.2018.08.010_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/annonc\/mdv600","article-title":"Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy","volume":"27","author":"Tannock","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.08.010_bib32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2018.08.010_bib33","series-title":"Assessment report: Zytiga (abiraterone acetate)","author":"European Medicines Agency (EMA)","year":"2017"},{"key":"10.1016\/j.ejca.2018.08.010_bib34","series-title":"2014 ESMO congress. Madrid, Spain","article-title":"Chemohormonal therapy vs. androgen ablation randomized trial for extensive disease in prostate cancer (CHAARTED). Presentation E3805. Slide 15 - patient characteristics: high volume","author":"Sweeney","year":"2014"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491831147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491831147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:58Z","timestamp":1760732578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491831147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":34,"alternative-id":["S095980491831147X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.08.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}